Integra Posts $14.9 Million Profit Against Year-Ago Loss, With Revenue Up 2.3% To $411.2 Million

Third-quarter sales included an approximate $7 million hit from the Cincinnati flood, and Tissue Reconstruction revenue fell 2.2%.

Share
Integra Posts $14.9 Million Profit Against Year-Ago Loss, With Revenue Up 2.3% To $411.2 Million

Integra LifeSciences reported third-quarter revenue of $411.2 million, up 2.3% as reported and 2.5% organically, in an 8-K filed Wednesday. The figure includes an approximate $7 million revenue hit from flood damage at its Cincinnati plant, and the company swung to a standard-accounting profit of $14.9 million from a year-ago loss.

What the results show

Standard-accounting earnings were $0.19 per diluted share, against a loss of $0.07 a year earlier, the earnings release says. Adjusted earnings were $0.59 per share, versus $0.54.

Specialty Surgery, about 70% of revenue, grew 3.9% to $304.1 million. Within it, Neuro sales rose 6.5% organically, Instruments fell 0.9% on order timing, and ENT fell 1.1%, largely on sinus balloons. The flood weighed on this segment.

Tissue Reconstruction revenue fell 2.2% to $107.1 million. Wound reconstruction declined by a low single-digit rate, as growth in DuraSorb and PriMatrix was offset by declines in MicroMatrix and Integra Skin. Corporate Partnerships, the new name for the Private Label business, was roughly flat.

Adjusted gross margin was 61.1%, down from 62.9%. Adjusted EBITDA was $79.8 million, or 19.4% of revenue, against $78.5 million, or 19.5%.

Cash, refinancing and guidance

Operating cash flow was $96.0 million, and free cash flow was $85.7 million versus $25.8 million a year earlier, the company's tables show. Net debt ended the quarter at $1.5 billion, with a leverage ratio of 3.8x.

On October 19, Integra completed a $2.1 billion refinancing: a $1.65 billion senior secured credit facility and $450 million of 9.5% senior secured notes due 2033. Amended covenants step the maximum net leverage ratio down to 4.25x during 2027, against 4.0x under the old terms. The company expects its interest rate to rise by an amount near the high end of the previously communicated 100- to 200-basis-point range.

Full-year guidance is $1.634 billion to $1.654 billion in revenue and $2.30 to $2.40 in adjusted earnings per share, consistent with the outlook the company gave on October 2. Fourth-quarter revenue is guided to $413 million to $433 million, with adjusted earnings of $0.61 to $0.71 per share. The company says the outlook reflects the Cincinnati disruption and a revised view of Tissue Reconstruction.

What management said

Chairman and CEO Stuart Essig called the quarter "mixed results across our portfolio," citing "softer-than-expected results in Tissue Reconstruction." The SurgiMend relaunch is planned for the fourth quarter of 2026. Management held its call at 8:30 a.m. ET Wednesday.

Fourth-quarter revenue guidance of $413 million to $433 million is the next test of the Cincinnati recovery.

Sources

More on Integra LifeSciences

All Integra LifeSciences (IART) coverage →